Intrahepatic cholestasis of pregnancy (ICP) is the most common, reversible, and closely related to pregnancy condition characterized by elevated levels of bile acids (BAs) in blood serum and an increased risk of adverse perinatal outcomes. Due to the complex interactions between the mother and the fetus in metabolism and transplacental BAs transport, ICP is classified as a fetal-maternal disease. The disease is usually mild in pregnant women, but it can be fatal to the fetus, leading to numerous complications, including intrauterine death. The pathophysiology of the disease is based on inflammatory mechanisms caused by elevated BA levels. Although ICP cannot be completely prevented, its early diagnosis and prompt management significantly reduce the risk of fetal complications, the most serious of which is unexpected intrauterine death. It is worth emphasizing that all diagnostics and management of ICP during pregnancy are based on BA levels. Therefore, it is important to standardize the criteria for diagnosis, as well as recommendations for management depending on the level of BAs, which undoubtedly determines the impact on the fetus. The purpose of this review is to present the potential and importance of BAs in the detection and rules of medical procedure in ICP.
CITATION STYLE
Majsterek, M., Wierzchowska-Opoka, M., Makosz, I., Kreczyńska, L., Kimber-Trojnar, Ż., & Leszczyńska-Gorzelak, B. (2022, November 1). Bile Acids in Intrahepatic Cholestasis of Pregnancy. Diagnostics. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/diagnostics12112746
Mendeley helps you to discover research relevant for your work.